Items tagged with HIV coinfection
CROI 2019: TB preventive therapy safe in pregnant women (post)
SEATTLE – Pregnant women who are infected with HIV and are at risk of tuberculosis co-infection can undergo isoniazid prevention therapy without causing harm to themselves or their babies, researchers suggested here.
CROI 2019: Dolutegravir can be given with 3HP to prevent TB without dose adjustment (post)
Dolutegravir (DTG) can be given with short-course TB preventive therapy of 12 once-weekly rifapentine/isoniazid (3HP) without dose adjustment, according to data from the DOLPHIN trial, presented at CROI 2019. [1]
CROI 2019: Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity (post)
Adjusted doses of darunavir/ritonavir (DRV/r) with rifampicin (RIF) were associated with unacceptable risk of hepatotoxicity and a reduction in DRV trough concentrations in a pharmacokinetic (PK) study, conducted in South Africa, presented at CROI 2019.
One-month regimen noninferior for preventing HIV-related TB (post)
For HIV-infected patients, a one-month regimen of rifapentine and isoniazid is noninferior to nine months of isoniazid alone for preventing tuberculosis, according to a study published in the March 14 issue of the New England Journal of Medicine.
HIV/TB co-infection: Tunneling towards better diagnosis (post)
1.2 million people in the world are co-infected by Mycobacterium tuberculosis, the bacteria which causes tuberculosis, and HIV-1. This combination is deadly: it makes patient diagnosis and treatment difficult, and increases the pathogenicity of these two infectious agents. An international team led by researchers at the CNRS and Inserm have revealed that in the presence of tuberculosis, HIV-1 moves from one cell to the next via nanotubes which form between macrophages, drastically increasing the percentage of infected cells. These findings appear in the 26 March 2019 edition of Cell Reports.
Efavirenz and rifampicin together reduce levels of injectable contraception (post)
Women with HIV receiving depot medroxyprogesterone acetate (DMPA), with efavirenz (EFV)-based ART and rifampicin (RIF)-based TB treatment, had lower MPA plasma levels compared with women not receiving the two drugs.
Accelerating action to end the TB and HIV epidemics in the Western Pacific Region (post)
The WHO Regional Office of the Western Pacific Region organised a ‘Joint TB and HIV programme managers meeting' to bring together key stakeholders to accelerate action to end the dual epidemics of TB and HIV in the region.
Xpert testing to find TB in people with advanced HIV at diagnosis saves lives, study finds (post)
In sub-Saharan Africa where the odds of dying within a year of starting treatment for HIV can still hover close to one-in-10, diagnosing and treating TB — a curable disease that remains the leading cause of death for people with the virus — at the point of HIV testing offers a life-saving opportunity to improve patients’ chances. That makes accurate, point of care testing all the more urgently needed in places like in rural Malawi, where an X-ray to identify TB, and treatment for the disease based on symptoms, can be out of reach during the wait for laboratory test results.
Successful dolutegravir-based ART for patients with TB/HIV co-infection (post)
Dolutegravir in combination with 2 non-nucleot(s)ide reverse transcriptase inhibitors (NRTIs) is well tolerated and may produce rapid virologic and immunologic responses in patients with tuberculosis (TB) and HIV who have not previously received treatment , according to a study published in Clinical Infectious Diseases.
Philippines: Rise in HIV cases increases likelihood of TB spread – experts (post)
MANILA, Philippines — The continued rise in the number of human immunodeficiency virus (HIV) cases is causing an additional burden to the prevalence of tuberculosis in the country, according to health experts.
Page 30 of 52 · Total posts: 0
←First 29 30 31 Last→